Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diazepinomicin - Amo Pharma

Drug Profile

Diazepinomicin - Amo Pharma

Alternative Names: AMO 01; BU-4664L; ECO 04601; ECO 4601; TLN 4601

Latest Information Update: 28 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ecopia BioSciences
  • Developer AMO Pharma; BELLUS Health
  • Class Alkaloids; Antineoplastics; Benzodiazepinones; Small molecules
  • Mechanism of Action Apoptosis stimulants; Ras protein inhibitors; TSPO protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Telomeric 22q13 Monosomy Syndrome
  • No development reported Fragile X syndrome
  • Discontinued Glioblastoma

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for phase-I development in Fragile-X-syndrome in USA (IV, Infusion)
  • 24 Jun 2018 Biomarkers information updated
  • 10 Apr 2018 Phase-II clinical trials in Telomeric 22q13 Monosomy Syndrome in USA (IV) (NCT03493607)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top